We will be in Strasbourg on Tuesday and Wednesday next Week for Biofit 2017 event. We will have a booth on Eurasante space.

We will present our new robotic platform, HAPIx, dedicated to HCS and our new assays, especially on genotoxicity analysis (mutiparametric assay with micronucleus, gH2AX and PHH3 analysis in a same experiment).

We will present also our collaborative R&D programs on iPS, 3D culture and innovative 3D cellular models for phenotypic screening!

We will be really happy to discuss with you on our booth. Contact us now if you want to book a meeting. See you next week in Strasbourg!

This was a pleasure to be present at Advances in Cell Based Screening 2017 #ELRIGCBS17 congress in Gothenburg. Presentations during those two days were interesting showing new progress in technologies as in 3D cell culture and patients derived culture iPS cell. Phenotypic screening and machine learning are becoming the standard in the industry and will allow personalized medicine in a near future.

As an example Professor Neil Carragher from Edinburgh University has explained their phenotypic screen on glioma using patient derived culture, cell painting as described by Anne Carpenter from the Broad Institute of MIT as read-outs and machine learning for image and data analysis. Another topic of interest was from Vilja Pietiäinen (Institute for Molecular Medicine Finland – FIMM) showing their proof of concept for personalized medicine in oncology, on leukemia and solid tumors. They used genomic and phenotypic screening on patients derived cells on 2D and 3D culture with machine learning to choose the drugs which are the most effective for the patient. We were also very interested by topics about advances in 3D culture, especially for human hepatocytes as presented by Volker Laushke. Indeed, 3D culture of PHH and human derived PHH are part of two subjects from our R&D project InnovCell 3D, and Chopin.

Other talks from pharmaceutical industries as Astrazeneca and GSK showed also the interest of all these new technologies to be more efficient in drug research and development. We remember the presentation from Sinead Knight from AstraZeneca depicting the High-Throughput phenotypic screen to identify modulators of human pancreatic β-Cell proliferation for Type II Diabetes.

Discussions around our HCS Pharma ‘s booth (located close to the poster) were intense and have lead to new ideas and collaborations. Thanks of all of you visiting us! We hope to meet you all again at the next conference.

Your children came back to school  ? It is the same for Meryl Roudaut who also just begin his PhD training in collaboration with Pr Bertrand Cariou and Dr Karim Si-Tayeb from “l’institut du thorax”. The goal of his Ph D training is to develop and automate new innovative cellular 3D models from iPS cells coming from patient with familial hypercholesterolemia. This project is a little part of big project called CHOPIN! Thank you to them to give the opportunity to Meryl to do his Ph D and to start a collaboration between us! Thank you also to the ANRT, the French Research & Technology Agency, for their financial support to our R&D project. We wish a lot of succes to Meryl!

Using iPS, researchers are moving very quickly in understanding cell differentiation and already manage to recreate a mini-organ in vitro after 20-30 days of differentiation. These mini-organs of brain, liver, heart and so one can be used as in vitro assay to test efficiency of new drugs. Furthermore, new perspectives in personalized medicine also open in oncology, stem cells from cancerous tissue of the patient can be grown to produce a tumor organoid. From the patient cells to find new drug using phenotypic screening is now a new opportunity to innovate in medicine.

Source (in french) : http://www.sciencesetavenir.fr/sante/20160212.OBS4547/la-fabrique-de-micro-organes-humains.html

To incresase the relevance of the early stage of drug research process, using patient derived-cells is really the good way. This can be now feasible by using iPSCs. This is nicely described in the recent article published on GEN website.

“The ability to make induced pluripotent stem cells (iPSCs) from adult human somatic cells and use those iPSCs to produce any cell type in the human body opens new avenues for drug discovery. Human iPSCs can enable phenotypic screening efforts by supplying unlimited amounts of relevant cell types derived from diverse genetic backgrounds.

Newly available biobanks of high-quality iPSCs from hundreds of donors, representing a growing number of disease states, are making it easier to create robust phenotypic screening programs. By 2018, publicly available biobanked iPSC lines are expected to number in the thousands (Novak, 2015).”

To read the full article published on GEN, follow this link : http://www.genengnews.com/gen-articles/enabling-phenotypic-screening/5657/

%d bloggers like this: